Search
avacincaptad pegol (Izeray)
Indications:
- geographic atrophy secondary to age-related macular degeneration
Dosage:
- 2 mg, 0.1 mL of 20 mg/mL solution intravitreal injection once monthly
- for use up to 12 months
20 mg/mL in single-dose vial
Adverse effects:
- most common
- conjunctival hemorrhage (13%)
- increased intraocular pressure (9%)
- blurred vision (8%)
- neovascular age-related macular degeneration (7%)
- other
- endophthalmitis
- retinal detachment
Mechanism of action:
- complement inhibitor
- PEGylated oligonucleotide that binds to & inhibits complement C5
- by inhibiting C5, avacincaptad pegol may prevent its cleavage to C5a & C5b thus decreasing membrane attack complex (MAC) formation.
General
ophthalmic agent (eyedrops)
References
- HIGHLIGHTS OF PRESCRIBING INFORMATION
Izeray (avacincaptad pegol intravitreal solution)
https://ivericbio.com/wp-content/uploads/IZERVAY-avacincaptad-pegol-intravitreal-solution-PI_Final_8.4.23.pdf